Mechanisms of fibroblast cell therapy for dystrophic epidermolysis bullosa: high stability of collagen VII favors long-term skin integrity
about
Molecular therapeutics for heritable skin diseasesAdvances in understanding and treating dystrophic epidermolysis bullosaOne goal, different strategies--molecular and cellular approaches for the treatment of inherited skin fragility disordersCell therapy in dermatology.Polymeric Nanoparticles to Combat Squamous Cell Carcinomas in Patients with Dystrophic Epidermolysis Bullosa.Lentiviral Engineered Fibroblasts Expressing Codon-Optimized COL7A1 Restore Anchoring Fibrils in RDEB.Novel molecular therapies for heritable skin disordersFrom marrow to matrix: novel gene and cell therapies for epidermolysis bullosa.From Mesoderm to Mesodermatology: Bone Marrow Mesenchymal Cells Heal Skin Wounds.Allogeneic blood and bone marrow cells for the treatment of severe epidermolysis bullosa: repair of the extracellular matrix.Patient-specific naturally gene-reverted induced pluripotent stem cells in recessive dystrophic epidermolysis bullosaNovel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa.The collagen family.Concise review: Transplantation of human hematopoietic cells for extracellular matrix protein deficiency in epidermolysis bullosa.Bone marrow transplantation in epidermolysis bullosa.The long and winding road that leads to a cure for epidermolysis bullosa.Gene therapy: pursuing restoration of dermal adhesion in recessive dystrophic epidermolysis bullosa.Treatment of hereditary epidermolysis bullosa: updates and future prospects.Inherited blistering skin diseases: underlying molecular mechanisms and emerging therapies.Therapies for inherited skin fragility disorders.COL7A1 Editing via CRISPR/Cas9 in Recessive Dystrophic Epidermolysis Bullosa.Next generation human skin constructs as advanced tools for drug development.High Local Concentrations of Intradermal MSCs Restore Skin Integrity and Facilitate Wound Healing in Dystrophic Epidermolysis Bullosa.Dominant-negative effects of COL7A1 mutations can be rescued by controlled overexpression of normal collagen VII.Topical application of recombinant type VII collagen incorporates into the dermal-epidermal junction and promotes wound closure.Collagen VII plays a dual role in wound healing.Long-term type VII collagen restoration to human epidermolysis bullosa skin tissue.Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patientsHigh levels of type VII collagen expression in recessive dystrophic epidermolysis bullosa cutaneous squamous cell carcinoma keratinocytes increases PI3K and MAPK signalling, cell migration and invasion.A non-viral gene therapy for treatment of recessive dystrophic epidermolysis bullosa.[New developments in hereditary blistering skin diseases].Alterations in basement membrane immunoreactivity of the diabetic retina in three diabetic mouse models.Current and Future Perspectives of Stem Cell Therapy in Dermatology.Management of severe epidermolysis bullosa by haematopoietic transplant: principles, perspectives and pitfalls.Genetically corrected iPSCs as cell therapy for recessive dystrophic epidermolysis bullosa.
P2860
Q26865551-CA8BB226-7B26-4952-8FB5-B1C63BC27639Q27006669-0DD6753A-3F03-4C86-A0F1-5977FD320A7AQ27026711-1B9ABA84-F1C4-4612-99C7-3051AEB6B08EQ33653689-FDF61205-B780-4063-9391-598C36BE8A5BQ34678948-CBEDBAA7-3F09-4E47-8449-BB2C03F543B0Q36595683-E12CA938-1077-4133-A224-93AE138BAED9Q36610899-746FA4EB-9A5D-4CFE-93AE-323CDD325F6BQ36756725-C7920A54-037D-4736-B300-F8510207D40CQ36757030-4CF6B5DD-3B73-49BA-AF9D-E671F8583408Q37649276-E961DBBE-3D29-43E0-A906-0CFB23A3071CQ37707008-A3F21B02-FAF5-49F7-9469-30376EE37B71Q37712686-90D6728F-39DA-45D8-8A7E-8AA313389AA1Q37855335-32F7029A-7E11-48CC-A440-834AB0B28D60Q37873887-4F0E851E-7B10-4E08-ADA7-470071E05EC1Q38067450-A9B53F36-85A4-4F43-BCE0-5BEE1A2844F1Q38119245-4ADDFF3A-0BC8-4959-8A02-48BA768B9323Q38150897-A52A6EDB-C997-4F70-AED2-47B48593D94EQ38176832-B8402CEE-BC6C-4733-A377-8F3A9CC8BCB9Q38180485-D6F04269-40DB-4B92-AA65-C04981589FE2Q38444460-02BF6159-5712-4099-AE55-26871A8C0CADQ38628478-E5248B59-6B6A-4899-BF01-0999DA4C2654Q38673576-6219A843-3320-4BE9-B865-3534A4E723DDQ39789694-9F07697B-E59B-498A-BF52-E2C712DCB0D7Q39804335-43026C9E-740F-4FEB-9E4B-B1B4C2303E52Q41815771-67F022C4-1EB7-4530-AB9A-70A5DE695950Q41843053-D85E4F26-0E35-4B36-BF65-96DF81576FEBQ41956259-51AC965E-953B-4C55-BB14-141B240D7B6FQ42644106-6DC6BB25-F726-499D-965D-AAE71C52D8A7Q43570408-1694B96F-827C-4373-853A-BF2169167B3EQ45885398-80143D10-6095-4439-B0BA-485C3F602656Q46363533-D39C0DAC-2F91-4081-977B-EE5D6458052BQ46536885-D985D6F0-C1BB-4DBE-8B0A-EE5F7E8D74F2Q47102946-3E4D951A-BFCB-442A-9E5F-964F21FA67ACQ53143040-A4351296-032E-4C00-B0E0-393EC613F859Q53770761-192A1737-B56B-4C84-AF88-229A53408683
P2860
Mechanisms of fibroblast cell therapy for dystrophic epidermolysis bullosa: high stability of collagen VII favors long-term skin integrity
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Mechanisms of fibroblast cell ...... avors long-term skin integrity
@ast
Mechanisms of fibroblast cell ...... avors long-term skin integrity
@en
type
label
Mechanisms of fibroblast cell ...... avors long-term skin integrity
@ast
Mechanisms of fibroblast cell ...... avors long-term skin integrity
@en
prefLabel
Mechanisms of fibroblast cell ...... avors long-term skin integrity
@ast
Mechanisms of fibroblast cell ...... avors long-term skin integrity
@en
P2093
P2860
P356
P1433
P1476
Mechanisms of fibroblast cell ...... avors long-term skin integrity
@en
P2093
Anja Fritsch
Claudia Mack
Ingrid Hausser
Marcel L Müller
Oliver Paul
Patrick Ruther
Stefan Loeckermann
Thomas M Magin
P2860
P304
P356
10.1038/MT.2009.144
P577
2009-06-30T00:00:00Z